Skip to main content
main-content
Erschienen in: World Journal of Surgery 8/2015

01.08.2015 | Original Scientific Report

Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension

verfasst von: F. Dumont, Y. Goudard, C. Caramella, D. Goéré, E. Baudin, D. Elias

Erschienen in: World Journal of Surgery | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Pancreatic neuroendocrine tumors (PNET) locally advanced may lead to significant local symptoms especially segmental portal hypertension (SPH) with risk of bleeding. The aim of our study was to evaluate the role of SPH on the PNET management in an expert center.

Methods

Forty-two patients treated for locally advanced PNET with SPH between January 1984 and December 2012 were retrospectively analyzed.

Results

The median age was 55 years (25–75). The median tumor size was 7.5 cm (3–20). Thirty four (80.9 %) patients were metastatic mainly in the liver (n = 33, 79 %) with a frequent (n = 16, 38.1 %) involvement >20 %. The surgery was impossible because of SPH in 7 (16.6 %) cases. Pancreatic resection was performed in 28 (66.7 %) cases by distal pancreatectomy. Neoadjuvant chemotherapy (n = 24, 57 %) had no impact on SPH with no modification of collateral circulation. Among operated on patients, complete macroscopic resection was obtained in 19 (67.8 %) patients. The mortality and severe morbidity rate was respectively 3.6 and 18 %. Five year overall survival (OS) was similar in operated and no operated patients. (61 %; p = 0.64). The 5-year OS was 77.9 or 55.4 % in patients who underwent a complete or incomplete macroscopic resection of primary and metastases, respectively.

Conclusion

PNET resection associated with SPH is feasible with a low morbimortality. SPH was not improved by chemotherapy. Prolonged survival was observed after complete macroscopic resection.
Literatur
1.
Zurück zum Zitat Franko J, Feng W, Yip L, Genovese E, Moser AJ (2010) Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2158 patients. J Gastrointest Surg 14:541–548 PubMedCrossRef Franko J, Feng W, Yip L, Genovese E, Moser AJ (2010) Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2158 patients. J Gastrointest Surg 14:541–548 PubMedCrossRef
2.
Zurück zum Zitat Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK (2011) Prognostic validity of a novel American Joint Committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044–3049 PubMedCrossRef Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK (2011) Prognostic validity of a novel American Joint Committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044–3049 PubMedCrossRef
3.
Zurück zum Zitat Evans DB, Skibber JM, Lee JE et al (1993) Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114:1175–1181 PubMed Evans DB, Skibber JM, Lee JE et al (1993) Nonfunctioning islet cell carcinoma of the pancreas. Surgery 114:1175–1181 PubMed
4.
Zurück zum Zitat Solorzano CC, Lee JE, Pisters PW et al (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085 PubMedCrossRef Solorzano CC, Lee JE, Pisters PW et al (2001) Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085 PubMedCrossRef
6.
Zurück zum Zitat Koklu S, Coban S, Yuksel O, Arhan M (2007) Left-sided portal hypertension. Dig Dis Sci 52:1141–1149 PubMedCrossRef Koklu S, Coban S, Yuksel O, Arhan M (2007) Left-sided portal hypertension. Dig Dis Sci 52:1141–1149 PubMedCrossRef
7.
Zurück zum Zitat Shah SA, Amarapurkar AD, Prabhu SR, Kumar V, Gangurde GK, Joshi RM (2010) Splenic mass and isolated gastric varices: a rare presentation of a neuroendocrine tumor of the pancreas. JOP 11:444–445 PubMed Shah SA, Amarapurkar AD, Prabhu SR, Kumar V, Gangurde GK, Joshi RM (2010) Splenic mass and isolated gastric varices: a rare presentation of a neuroendocrine tumor of the pancreas. JOP 11:444–445 PubMed
8.
Zurück zum Zitat Joyce DL, Hong K, Fishman EK, Wisell J, Pawlik TM (2008) Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. World J Surg Oncol 28:6–80 Joyce DL, Hong K, Fishman EK, Wisell J, Pawlik TM (2008) Multi-visceral resection of pancreatic VIPoma in a patient with sinistral portal hypertension. World J Surg Oncol 28:6–80
9.
Zurück zum Zitat Singhal D, Kakodkar R, Soin AS, Gupta S, Nundy S (2006) Sinistral portal hypertension—a case report. JOP 7:670–673 PubMed Singhal D, Kakodkar R, Soin AS, Gupta S, Nundy S (2006) Sinistral portal hypertension—a case report. JOP 7:670–673 PubMed
10.
Zurück zum Zitat Watase M, Sakon M, Monden M et al (1992) A case of splenic vein occlusion caused by the intravenous tumor thrombus of nonfunctioning islet cell carcinoma. Surg Today 22:62–65 PubMedCrossRef Watase M, Sakon M, Monden M et al (1992) A case of splenic vein occlusion caused by the intravenous tumor thrombus of nonfunctioning islet cell carcinoma. Surg Today 22:62–65 PubMedCrossRef
11.
Zurück zum Zitat Wang H, Bie P, Zhang L (2011) Refractory gastroesophageal variceal bleeding secondary to neuroendocrine carcinoma in the pancreatic tail. Pancreatology 11:228–232 PubMedCrossRef Wang H, Bie P, Zhang L (2011) Refractory gastroesophageal variceal bleeding secondary to neuroendocrine carcinoma in the pancreatic tail. Pancreatology 11:228–232 PubMedCrossRef
12.
Zurück zum Zitat Falconi M, Bartsch DK, Eriksson B et al (2012) ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well differentiated pancreatic non-functionning tumors. Neuroendocrinology 95:120–134 PubMedCrossRef Falconi M, Bartsch DK, Eriksson B et al (2012) ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well differentiated pancreatic non-functionning tumors. Neuroendocrinology 95:120–134 PubMedCrossRef
13.
Zurück zum Zitat Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401 PubMedCentralPubMedCrossRef Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401 PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Elias D, Goere D, Leroux G et al (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35:1092–1097 PubMedCrossRef Elias D, Goere D, Leroux G et al (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35:1092–1097 PubMedCrossRef
15.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213 PubMedCentralPubMedCrossRef Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213 PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13 PubMedCrossRef Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8–13 PubMedCrossRef
17.
Zurück zum Zitat Abu Hilal M, McPhail MJ, Zeidan BA, Jones CE, Johnson CD, Pearce NW (2009) Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it? JOP 10:276–279 PubMed Abu Hilal M, McPhail MJ, Zeidan BA, Jones CE, Johnson CD, Pearce NW (2009) Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it? JOP 10:276–279 PubMed
18.
Zurück zum Zitat Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132:976–982 PubMedCrossRef Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132:976–982 PubMedCrossRef
19.
Zurück zum Zitat Metairie S, Azoulay D, Castaing D (2003) Portal collateral circulation and pancreatic carcinoma: bypass the obstacle. Gastroenterol Clin Biol 27:923–926 PubMed Metairie S, Azoulay D, Castaing D (2003) Portal collateral circulation and pancreatic carcinoma: bypass the obstacle. Gastroenterol Clin Biol 27:923–926 PubMed
20.
Zurück zum Zitat Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138:859–866 PubMedCrossRef Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT (2003) Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 138:859–866 PubMedCrossRef
21.
Zurück zum Zitat Teh SH, Deveney C, Sheppard BC (2007) Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 193:610–613 PubMedCrossRef Teh SH, Deveney C, Sheppard BC (2007) Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg 193:610–613 PubMedCrossRef
22.
Zurück zum Zitat Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL (2002) En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 6:147–157 PubMedCrossRef Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL (2002) En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 6:147–157 PubMedCrossRef
23.
Zurück zum Zitat Grutzmann R, Ruckert F, Hippe-Davies N, Distler M, Saeger HD (2012) Evaluation of the International Study Group of Pancreatic Surgery definition of post-pancreatectomy hemorrhage in a high-volume center. Surgery 151:612–620 PubMedCrossRef Grutzmann R, Ruckert F, Hippe-Davies N, Distler M, Saeger HD (2012) Evaluation of the International Study Group of Pancreatic Surgery definition of post-pancreatectomy hemorrhage in a high-volume center. Surgery 151:612–620 PubMedCrossRef
24.
25.
Zurück zum Zitat Bernades P, Baetz A, Levy P, Belghiti J, Menu Y, Fekete F (1992) Splenic and portal venous obstruction in chronic pancreatitis—a prospective longitudinal study of a medical-surgical series of 266 patients. Dig Dis Sci 37:340–346 PubMedCrossRef Bernades P, Baetz A, Levy P, Belghiti J, Menu Y, Fekete F (1992) Splenic and portal venous obstruction in chronic pancreatitis—a prospective longitudinal study of a medical-surgical series of 266 patients. Dig Dis Sci 37:340–346 PubMedCrossRef
26.
27.
Zurück zum Zitat Loftus JP, Nagorney DM, Ilstrup D, Kunselman AR (1993) Sinistral portal hypertension—splenectomy or expectant management. Ann Surg 217:35–40 PubMedCentralPubMedCrossRef Loftus JP, Nagorney DM, Ilstrup D, Kunselman AR (1993) Sinistral portal hypertension—splenectomy or expectant management. Ann Surg 217:35–40 PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Delaunoit T, Ducreux M, Boige V et al (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40:515–520 PubMedCrossRef Delaunoit T, Ducreux M, Boige V et al (2004) The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40:515–520 PubMedCrossRef
29.
Zurück zum Zitat Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523 PubMedCrossRef Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523 PubMedCrossRef
30.
Zurück zum Zitat Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771 PubMedCrossRef Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771 PubMedCrossRef
31.
Zurück zum Zitat Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275 PubMedCrossRef Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275 PubMedCrossRef
32.
Zurück zum Zitat Comerota AJ (2012) The future of deep veinous thrombosis and post-thrombotic syndrome in 2020. Phlebology 27:95–102 PubMedCrossRef Comerota AJ (2012) The future of deep veinous thrombosis and post-thrombotic syndrome in 2020. Phlebology 27:95–102 PubMedCrossRef
33.
Zurück zum Zitat Elias D, Lefevre JH, Duvillard P et al (2010) Hepatic metastases from neuroendocrine tumors wuth a “thin slice” pathological examination. Ann Surg 251:307–310 PubMedCrossRef Elias D, Lefevre JH, Duvillard P et al (2010) Hepatic metastases from neuroendocrine tumors wuth a “thin slice” pathological examination. Ann Surg 251:307–310 PubMedCrossRef
34.
Zurück zum Zitat Leboulleux S, Dromain C, Vataire AL et al (2008) Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93:3021–3028 PubMedCrossRef Leboulleux S, Dromain C, Vataire AL et al (2008) Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93:3021–3028 PubMedCrossRef
Metadaten
Titel
Therapeutic Strategies for Advanced Pancreatic Neuroendocrine Tumors with Segmental Portal Hypertension
verfasst von
F. Dumont
Y. Goudard
C. Caramella
D. Goéré
E. Baudin
D. Elias
Publikationsdatum
01.08.2015
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 8/2015
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3030-8

Weitere Artikel der Ausgabe 8/2015

World Journal of Surgery 8/2015 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.